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The architecture of EGFR’s basal complexes reveals
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Our current understanding of epidermal growth factor receptor (EGFR) autoinhibition is
based on X-ray structural data of monomer and dimer receptor fragments and does not
explain how mutations achieve ligand-independent phosphorylation. Using a repertoire of
imaging technologies and simulations we reveal an extracellular head-to-head interaction
through which ligand-free receptor polymer chains of various lengths assemble. The archi-
tecture of the head-to-head interaction prevents kinase-mediated dimerisation. The latter,
afforded by mutation or intracellular treatments, splits the autoinhibited head-to-head
polymers to form stalk-to-stalk ﬂexible non-extended dimers structurally coupled across the
plasma membrane to active asymmetric tyrosine kinase dimers, and extended dimers cou-
pled to inactive symmetric kinase dimers. Contrary to the previously proposed main auto-
inhibitory function of the inactive symmetric kinase dimer, our data suggest that only
dysregulated species bear populations of symmetric and asymmetric kinase dimers that
coexist in equilibrium at the plasma membrane under the modulation of the C-terminal
domain.
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The epidermal growth factor receptor (EGFR or HER1/ErbB1) is the founding member of the human EGFR tyr-osine kinase family (HER2/ErbB2/Neu, HER3/ErbB3, and
HER4/ErbB4)1. EGFR plays a fundamental signalling role in cell
growth and is frequently hyper-activated in human cancers via
mutation and/or overexpression2. This driving role in malignancy
has made EGFR a key target for anti-cancer therapy3,4.
An EGFR monomer consists of an N-terminal ligand-binding
extracellular module (ECM) connected to an intracellular module
(ICM) by a single-pass transmembrane (TM) helix (Fig. 1a). The
ECM comprises four domains (DI–DIV) and adopts a tethered
conformation via an interaction between DII and DIV5. The ICM
includes a short juxtamembrane (JM) segment, a tyrosine kinase
domain (TKD) and a disordered carboxy-terminal region, locus
of the key tyrosine phosphorylation sites6,7. Ligand binding sta-
bilises the extended conformation of the ECM promoting the
formation of back-to-back dimers8,9 (Fig. 1a). Subsequent EGFR
signalling across the plasma membrane depends on an allosteric
interaction between an activator and receiver kinase effected
through an asymmetric TKD (aTKD) dimer10. Signal transduc-
tion also requires ligand-bound EGFR oligomers11,12 formed by
face-to-face interactions between back-to-back dimers12 (Fig. 1b).
Evidence has accumulated over the years for ligand-free EGFR
dimers and oligomers (see e.g. refs. 13–21). However, the
mechanisms by which ligand-independent activation of non-
monomers is prevented remain unclear. Nonetheless, it is widely
believed that autoinhibition is related to the adoption of an
inactive symmetric TKD (sTKD) dimer revealed by X-ray
structures of EGFR TKDs bearing the V924R (or V948R) and
I682Q mutations at the C-lobe and N-lobe, which inhibit aTKD
dimer formation (PDB ID 3GT8 (ref. 22), 2GS7 (ref. 10), and
5CNN (ref. 6)). The sTKD was putatively associated to a spec-
ulative side-to-side ECM tethered dimer20 (Fig. 1c), presumably
because this would provide a fail-safe approach to autoinhibition.
Alternatively, molecular dynamics (MD) simulations23 suggested
that the sTKD dimer is coupled via a C-crossing TM domain
dimer to a ligand-free back-to-back dimer analogous to the X-ray
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Fig. 1 Models of ligand-free and ligand-bound EGFR complexes. a Top left: Cartoon of an EGFR monomer5. Top right: A ligand-bound back-to-back
extracellular dimer8,9. This is linked to the catalytically active asymmetric TKD (aTKD) dimer10 by an N-terminal crossing transmembrane (TM) dimer40
and an antiparallel juxtamembrane-A (JM-A) helical dimer22. b Cartoon of the extracellular portion and TM domains of ligand-bound EGFR polymers
formed by alternating back-to-back and face-to-face interfaces12. Two EGF molecules are bound at the end-receptors capping the polymer chain with a
2N:2 receptor/ligand stoichiometry. An 8:2 octamer is shown (intracellular regions not depicted). c Cartoon of a speculative ligand-free side-to-side dimer
that would putatively combine the double autoinhibition of a tethered extracellular domain and a symmetric tyrosine kinase domain (sTKD) dimer5,20,22.
d Cartoon of a ligand-free extended back-to-back dimer coupled via a TM domain C-crossing dimer to an sTKD dimer (modiﬁed from Arkhipov et al.23).
e Cartoon of a stalk-to-stalk tethered dimer coupled via an N-crossing TM domain dimer to the aTKD dimer induced by TKI binding in the C-terminal
domain truncated Δ998-EGFR (modiﬁed from Lu et al.26). For all panels ECM domains I and III are in red, II and IV in blue, EGF ligand is in green, plasma
membrane in yellow, TM in teal, JM in dark grey, TKD in light grey
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SAXS data from Caenorhabditis elegans EGFR16 (Fig. 1d). In this
back-to-back dimer, which resembles the ligand-bound dimer,
the autoinhibitory heavy lifting would be done by the sTKD
dimer alone25. A ﬂexible ECM dimer held by DIV–DIV contacts
by the plasma membrane was also suggested by electron micro-
scopy (EM) images of puriﬁed, near-full-length Δ998-EGFR26,27
(Fig. 1e). This stalk-to-stalk dimer is promoted by kinase-
mediated interactions in response to the binding of type I tyrosine
kinase inhibitors (TKIs), which reversibly bind the ATP-binding
pocket stabilising the aTKD dimer26 inhibiting C-terminal
phosphorylation. The challenge is the lack of high-resolution
methods on cells, which has made it impossible so far to obtain
evidence on the architecture of non-monomer ligand-free species.
Here we exploit the nanoscale resolution of ﬂuorophore loca-
lisation imaging with photobleaching (FLImP)12,28–30 in a multi-
technique study including two-colour single particle tracking
(SPT)31, ﬂuorescence resonance energy transfer (FRET)32,33, and
MD simulations23,34 to investigate ligand-free non-monomer
species on cells. The results reveal structural insights on the
inactive species and on how mutations circumvent the auto-
inhibition of the basal state.
Results
Monomers and dimers and oligomers populate the cell surface.
We used FLImP on Chinese Hamster Ovary (CHO) cells
expressing ~105 wild-type EGFR (wtEGFR) copies/cell, main-
tained by an inducible Tet-ON promoter35 (Fig. 2a). FLImP
measures pairwise lateral separations between identical ﬂuor-
ophores with ~5–7 nm resolution, returning normalised dis-
tributions in the 0–60 nm range, which is ideal to investigate
EGFR dimers and oligomers12. We conjugated CF640R ﬂuor-
ophore to the single cysteine of an anti-EGFR Afﬁbody which
binds DIII of EGFR’s ECM without activating the receptor36 and
accumulated a FLImP histogram of DIII–DIII separations from
ligand-free wtEGFR complexes. Bayesian parameter estimation
with Bayesian Information Criterion (BIC)12 objectively decom-
posed the FLImP histogram into a sum of ﬁve peak components
at 5, 13, 22, 30, and 46 nm (Fig. 2b). An EGFR dimer has two
DIIIs and must give rise to a unique DIII–DIII separation. This
must be <~20 nm, given the <3.7 nm size of Afﬁbody probes37
and the ~5–8 nm size of the EGFR monomer5,8,9. Multiple
separations >20 nm and periodic DIII–DIII components therefore
report ligand-free wtEGFR oligomers larger than dimers and
stoichiometric extracellular interactions, respectively. These
results agree with previous data from T47D cells28, which express
10-fold fewer EGFR copies/cell, indicating that the ligand-free
structures formed by EGFR are independent of receptor
expression.
Being a pairwise measurement, FLImP is insensitive to
monomers. To estimate the relative proportions of monomers
and other species, we used model-free photobleaching image
correlation spectroscopy (pbICS)38 analysis, which we applied to
CHO cells expressing wtEGFR labelled with an Alexa 488-
Afﬁbody ﬂuorescent derivative (Fig. 2c). The results suggest that
~65% of receptors are incorporated into dimers and larger
oligomers, consistent with previous estimates18,21,39.
A structural model of extracellular ligand-free dimers. The
nanoscale proximity between receptors in oligomers translates
into a local surface density of ~5000 receptors/μm2. This is above
that on cells overexpressing >2 × 106 EGFR copies/cell (~2000
receptors/μm2), where signiﬁcant phosphorylation occurs in the
absence of ligand40. In contrast, CHO cells expressing 20-fold
fewer receptors have low basal phosphorylation36 despite ~65% of
receptors forming non-monomer complexes. This suggests that
ligand-independent phosphorylation is inhibited in ligand-free
complexes, leaving two questions: what is their architecture and
how is autoinhibition achieved?
Among possibilities, we considered cyclic shapes41 and
polymer chains12 (Fig. 2d). Both architectures, when probed
with a 1:1 binder like Afﬁbody, predict a decreasing “ladder-like”
DIII–DIII separation intensity consistent with FLImP results.
However, the longest DIII–DIII separation (46 nm) (Fig. 2b) and
largest oligomer size (octamers) (Fig. 2c) are more consistent with
polymer chains. To test this further, we conjectured that, when
probed with a CF640R-EGF derivative, which only binds the
polymer ends12, each polymer chain would contribute a single
separation (Fig. 2d, right). Thus, the FLImP separation density
would move from short to long separations. This effect should be
more noticeable the fewer de novo complexes form after EGF
binding. A screen of EGF-induced particle colocalisation events
revealed that I942E-EGFR, a kinase domain mutation that allows
strong EGF-induced phosphorylation10, forms very few de novo
EGF-induced complexes (Supplementary Fig. 4). FLImP data
from I942E-EGFR display a decreasing ladder-like distribution of
DIII–DIII separations when probed with CF640R-Afﬁbody
(Fig. 2e) and a transfer of density to longer components when
probed with CF640R-EGF (Fig. 2f). These results are consistent
with polymer chain architectures.
To attempt to construct a structural model of a polymer chain
using long-timescale MD simulations, we searched for crystal
structures of the ECM monomer in which lattice contacts might
reveal previously unidentiﬁed oligomer interfaces. The structures
of EGFR co-crystallised with EgA1 (PDB ID 4KRO42) and 9G8
(PDB ID 4KRP42) veriﬁed this criterion. (EgA1 and 9G8 are
nanobodies (NBs) that bind DIII and stabilise the DII–DIV
tether42.) Figure 3a shows the monomer contacts in 4KRP. We
hypothesised that the tethered conformation and lack of two-fold
symmetry of this model, reminiscent of an X-ray structure of
HER2 co-crystallised with a designed ankyrin repeat protein43,
are reasonable initial points because both counteract the
formation of signalling dimers.
We then carried out two MD simulations (13.8 and 20 µs)
starting from the asymmetric dimer seen in the crystal packing of
4KRP, after removing 9G8-NB and adding the TM helix and the
lipid bilayer (Fig. 3b). In both simulations the ECM dimer arrived
at a head-to-head dimer conformation within 1.5 µs and
remained in this conformation to the end. This dimer
conformation is similar to the crystal dimer conformation in
that it remains asymmetric and open-ended and maintains the
trans interaction between the DIII of one protomer and the DIV
of the other, but it bears a trans interaction between DI and DII.
Moreover, the tethered conformation of the crystal structure was
consistently unstable, as in both simulations DI and DIII in both
protomers gained stable cis interaction with one another, giving
rise to a conformation similar to that in the proposed back-to-
back inactive dimer23 in terms of DI, DII, and DIII. Intriguingly,
the ECMs of neither of the two protomers in the head-to-head
conformation bear close contact with the membrane. Encoura-
gingly, the bulk of the amino acids involved in the head-to-head
interface (6–238) is missing in the constitutively active variant
EGFRvIII prevalent in glioblastoma (6–273)44. If amino acids
6–273 are deleted post-simulation in the model, the monomers
break apart (Fig. 3c), suggesting biological relevance.
We next added the 9G8-NBs to the starting ECM dimer and
similarly simulated a 9G8-bound head-to-head dimer up to 20 µs,
starting from the conformation seen in PDB 4KRP with the TM
helices and the lipid bilayer added (Fig. 3d). Consistent with the
two simulations of the “naked” dimer where 9G8-NB was
removed, the asymmetry and the open-endedness of the dimer
remained, the DIII–DIV trans interaction of the ECM dimer was
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stable, and the DI–DII trans interaction was developed. The
DI–DIII cis interaction again developed in both protomers,
reproducing the previously reported monomer conformation23.
Head-to-head interactions assemble curved polymer chains.
The head-to-head dimer can be extended into a higher-order
oligomer by incorporating additional protomers and repeating
the head-to-head interaction (Fig. 4a). pbICS data reveal that
~25% of species are dimers, ~10% trimers, and ~5% tetramers
and above (Fig. 4b). The fraction of each species as a function of
oligomer size looks approximately exponential consistent with a
step-wise polymerisation process. Curvature of the polymer chain
in the plane of the membrane would arise because the DIII–DIII
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r1 = 4.8 (–2.8+6.5) nm
r2 = 12.9 (–1.1+1.7) nm
r3 = 21.6 (–2.5+2.2) nm
r4 = 30.2 (–6.8+1.8) nm
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r1 = 5.0 (–5.0+5.6) nm
r5 = 56.5 (–2.2+4.2) nm
r2 = 18.3 (–3.2+4.2) nm
r3 = 27.2 (–2.3+2.3) nm
r4 = 45.8 (–3.5+5.7) nm
c
Fig. 2 FLImP measurement of pairwise DIII-binding Afﬁbody separations. a Cartoon of FLImP histograms. Left: A dimer (receptors, blue; label, red) gives
rise to one separation, the empirical posterior of which has a conﬁdence interval (CI) that depends on the combined localisation errors of the two
molecules28. CI size determines resolution. CIs less than the required resolution are retained according to signal-to-noise without bias12,28–30,36,
generating a FLImP distribution (grey) that is ﬁtted by the sum of a number of Rician peaks12. If oligomers are present and internally probed (middle) and/
or the distribution of species is inhomogeneous (right), the histogram contains multiple components12. b FLImP distribution (grey) of DIII–DIII separations
between CF640R-Afﬁbody molecules bound to wtEGFR on CHO cells, compiled from 68 FLImP measurements (CI≤ 7 nm), decomposed into a sum of ﬁve
components (coloured traces). The inset shows positions and error estimates. Additional statistics in Supplementary Fig. 1. The 4 nM concentration of
CF640R-Afﬁbody used labels ~20% of receptors (Supplementary Fig. 2) ensuring single particle detection29. FLImP is stochastic, thus independent of the
CF640R-Afﬁbody/receptor ratio if sufﬁcient data are collected, and uses ﬁxed cells to avoid relative receptor movements during measurements. However,
systematic studies failed to ﬁnd signiﬁcant artifacts12,36. cMolecular-normalised fraction of receptors in oligomer species on wtEGFR-expressing CHO cells
treated with 100 nM Alexa 488-Afﬁbody, determined by pbICS38. Results are the mean of seven replicates. Error bars show the SD. For more details see
Supplementary Fig. 3. d Cartoon showing expected FLImP distributions for a cyclic tetramer labelled with a 1:1 probe binder (like the Afﬁbody) (left), a
polymer chain labelled with a 1:1 probe binder (middle), and a polymer showing a 2N:2 labelling stoichiometry (like EGF)12 (N= receptor number) (right).
e FLImP distribution (grey) and peak decomposition of DIII–DIII separations reported by CF640R-Afﬁbody molecules bound to I942E-EGFR on the surface
of CHO cells, compiled from 36 FLImP measurements (CI≤ 7 nm), decomposed into a sum of four peak components (coloured traces). Positions and error
estimates are shown in the inset. f As e using 4 nM CF640R-EGF as a probe, compiled from 31 FLImP measurements (CI≤ 7 nm)
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separation between nearest neighbours is larger than DI–DI
(Fig. 3b). One can imagine such curved geometry would facilitate
receptor packing around the mouths of vesicles like, for example,
caveolae, which have a ~50 nm diameter45. The predicted
DIII–DIII separations (Fig. 4a, blue) are encouragingly consistent
with the experimentally measured separations (Fig. 2b;
Supplementary Fig. 1). Moreover, the largest separation resolved
(46 nm) corresponds to the prediction for the largest octamer
species detected by pbICS.
To further assess the possibility that this model represents the
architecture of non-monomer complexes, we conjectured that ΔC-
EGFR, which mirrors the amino acid sequence used in the
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Fig. 3 The structural model of ligand-free head-to-head EGFR dimers. a An open-ended oligomer model of 9G8-bound EGFR extracellular domains in the
inactive conformation built using the crystal contacts in the monomer structure in PDB ID 4KRP42, where 9G8-NB is coloured in cyan, EGFR DI in green, DII
(red), DIII (blue), and DIV (grey). b A simulation-generated dimer structure of free EGFR extracellular domains and their TM domains in the lipid bilayer.
The simulation was started from the crystal dimer of 9G8-bound EGFR extracellular domains in the tethered conformation in which the two copies of the
9G8-NB were removed from the simulation system. The images are based on the snapshot of the simulation at 20 µs. One of the two transmembrane
helices is visible (left and middle panels). The right panel shows the dimer viewed from the membrane, where the trans interaction between DI and DII and
the interaction between DIV and DIII are highlighted; the domains of monomer a and b are labelled. c By deleting residues 6–273 from the dimer structure
in b, the dimer structure directly mapped to the EGFRvIII glioblastoma mutant. As shown, this dimer structure is likely not viable in EGFRvIII as the trans
interaction between DI and DII is precluded by the deletion. d A simulation-generated dimer structure of 9G8-bound EGFR extracellular domains starting
from a crystal dimer of 9G8-bound EGFR extracellular domains in the tethered conformation. These images are based on the snapshot of the simulation at
20 µs. Invisible from this image are the TM helices embedded in the membrane. The right panel shows the 9G8-bound dimer viewed from the membrane,
where the trans-dimer interaction between DI and DII, and between DIV and DIII are highlighted
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simulated head-to-head dimer model (no ICM), should form
polymers consistent with the model. To test this, we probed
DIII–DIII separations on CHO cells that express ΔC-EGFR. The
separations resolved are consistent with the head-to-head poly-
merisation model predictions (Fig. 4c, Supplementary Fig. 7).
The model also predicts shorter DI–DI separations (Fig. 4a,
green). We tested this using a CF640R derivative of an anti-EGFR
EgB4 nanobody (EgB4-NB) that speciﬁcally binds DI of EGFR
without inducing activation42,46 (Supplementary Fig. 6). The
distribution of DI–DI separations is signiﬁcantly compressed
towards shorter values (Fig. 4d, Supplementary Figs. 8 and 9a–c).
Being smaller, fewer DI–DI separations are resolved, and those
resolved are consistent with model predictions.
Predicted distances from DI and DIII to the membrane were
tested by FRET32 (Fig. 4e). In parallel experiments we labelled DI
or DIII of wtEGFR with Alexa 488 derivatives of EgB4-NB or
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r2 = 15.0 (–2.2+4.5) nm
r3 = 26.5 (–4.7+4.7) nm
r4 = 42.3 (–5.6+4.5) nm
r1 = 3.9 (–2.1+4.1) nm
r2 = 13.3 (–3.4+1.8) nm
r3 = 37.7 (–2.2+2.5) nm
c
h
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Afﬁbody (FRET-donors) in the presence and absence of bound
9G8-NB. The plasma membrane was treated with dialkylcarbo-
cyanine probe DiIC18(5) (DiI) (FRET-acceptor). As shown in
Fig. 4e, DI is on average closer to the bilayer than DIII when 9G8-
NB is bound, while in its absence DI and DIII separations are
similar. The FRET measurement reports the average of mono-
mers and non-monomers; however, because these are predicted
to have similar extracellular conformations23, these FRET results
are consistent with the model predictions. In conclusion, our
FLImP and FRET data strongly favour the head-to-head interface
as the building block of ligand-free polymer chains.
ICMs in head-to-head polymers do not form dimers. We rea-
soned that extracellular and intracellular interactions should
together assemble more stable complexes than those assembled by
extracellular interactions alone. Given this, the contribution of the
ICMs to oligomerisation could be ascertained by comparing the
stability of the complexes formed by ΔC-EGFR (no ICM) and the
full-length wtEGFR and I942E-EGFR. This comparison is possi-
ble because ΔC-EGFR, wtEGFR, and I942E-EGFR form indis-
tinguishable polymer chains (Figs. 2b, e, 4c, Supplementary
Fig. 9d–f). For this investigation we used two-colour SPT, a
method previously used to report the incidence of pairwise
receptor particle interactions (colocalisation fraction) and their
duration (τON)12,14. Receptors were labelled with a 1:1 mixture of
Alexa 488-Afﬁbody and CF640R-Afﬁbody. Results show that ΔC-
EGFR forms the most complexes (Fig. 4f), which have an indis-
tinguishable duration to those formed by wtEGFR and I942E-
EGFR (Fig. 4g). These results argue against a signiﬁcant con-
tribution from intracellular interactions to oligomerisation
(Fig. 4h).
The aTKD dimer breaks head-to-head oligomers. The sizeable
separation between the N-termini of the TM helices in the head-
to-head dimer predicts that the stabilisation of the aTKD dimer,
by enforcing the N-crossing TM dimer40, would break the head-
to-head interaction. To test this, we stabilised the aTKD dimer by
treating wtEGFR-expressing CHO cells with erlotinib26, a type I
TKI47. The four DIII–DIII separation components resolved
(Fig. 5a) are at positions consistent with four of the ﬁve resolved
in the absence of erlotinib (Fig. 2b). We also determined the
proportion of measurements consistent with each of the mean
positions, an analysis that revealed a dominant 5 nm component
and a signiﬁcant decrease in separation density at longer positions
when compared with naked wtEGFR (Fig. 5b). This result cor-
relates aTKD dimer formation with oligomer loss.
To examine if oligomers split when the aTKD dimer is
stabilised in the absence of TKI, we treated CHO cells expressing
wtEGFR with methyl-β-cyclodextrin (MβCD), which depletes
cholesterol from the plasma membrane and activates EGFR in a
ligand-independent manner48 (Fig. 5c). The associated increase in
aTKD dimers returned results remarkably similar to those found
upon erlotinib treatment, namely DIII–DIII separations with a
dominant peak at ~4 nm and signiﬁcantly fewer oligomers
(Fig. 5b, d). Together these results support the notion that the
stabilisation of the aTKD dimer, either in the presence or absence
of erlotinib, disrupts oligomer formation.
Kinase-mediated stalk-to-stalk and back-to-back dimers.
Besides disrupting oligomers, the dominance of one DIII–DIII
separation component in the FLImP distributions of Fig. 5a, d
indicates that the stabilisation of the aTKD dimer promotes an
ECM dimer. This is supported by the increased receptor–receptor
colocalisation following erlotinib binding, as shown by SPT (p <
0.01, Kolmogorov–Smirnov test, two-tailed) (Fig. 5e). The for-
mation of erlotinib-bound aTKD dimers is also consistent with
the increased duration of the interactions between receptors when
compared with naked wtEGFR where only extracellular contacts
are present (p < 0.01, Kolmogorov–Smirnov test, two-tailed)
(Fig. 5f). The resolution of FLImP (~5–7 nm) is, however,
insufﬁcient to distinguish between the head-to-head dimer (~7
nm DIII–DIII separation) and the ECM dimer induced by erlo-
tinib (~5 nm DIII–DIII separation). We nevertheless reasoned
that these dimers are likely to be different because N-crossing TM
dimers would disrupt head-to-head interfaces.
To investigate the ECM dimer linked to the aTKD dimer, we
considered the stalk-to-stalk structure detected by EM26. This
dimer is upright, not-extended, and held by close C-terminal
DIV–DIV contacts that afford linking with the N-crossing TM
dimer and conformational ﬂexibility (Fig. 1e). To investigate the
presence of DIV–DIV contacts, we examined IIIV/KKRE-EGFR,
in which mutations I545K, I556K, I562R, and V592E (IIIV/
KKRE-EGFR) replace a hydrophophic surface of DIV with
charged amino acids11 (Fig. 5g). As shown in Fig. 5h, the IIIV/
KKRE-EGFR mutations should not disrupt head-to-head inter-
actions. Consistent with this, FLImP showed IIIV/KKRE-EGFR
forms as many head-to-head dimers and oligomers as wtEGFR
(Fig. 5b, i). The IIIV/KKRE-EGFR mutations are however poised
to disrupt DIV–DIV contacts. Thus, if formation of the aTKD
dimer is facilitated by DIV–DIV contacts in the ECM, then
cholesterol depletion should induce less phosphorylation in IIIV/
KKRE-EGFR. The absence of increased phosphorylation in
cholesterol-depleted IIIV/KKRE-EGFR-expressing cells is
Fig. 4 The architecture of ligand-free head-to-head polymers. a Polymer chain formed by repeating the head-to-head interface based on separations in
Supplementary Fig. 5a, b and Supplementary Tables 1 and 2 (DII and DIV excluded for simplicity). The intensity is graded according to pbICS results in b,
which show the data in Fig. 2c re-normalised to reveal the fractions of oligomer species on wtEGFR-expressing CHO cells treated with 100 nM Alexa 488-
Afﬁbody. Results are the mean of seven replicates. Error bars show SD. c FLImP distribution (grey) of DIII–DIII separations in ΔC-EGFR-expressing CHO
cells treated with 4 nM CF640R-Afﬁbody, from 41 FLImP measurements (CI≤ 6 nm). The inset shows positions and error estimates (additional statistics in
Supplementary Fig. 7). d As c but from ΔC-EGFR-expressing cells treated with 8 nM CF640R-EgB4-NB (DI–DI separations), from 32 FLImP measurements
(CI≤ 8 nm). Differences with the DIII–DIII distribution are signiﬁcant (Supplementary Fig. 8). e Left and centre: Cartoons showing a side view of DI and DIII
separations from the membrane in head-to-head complexes in the presence and absence of bound 9G8-NB based on Supplementary Fig. 5c–f and
Supplementary Table 3. Right: FRET-derived separations from the membrane-DiI to DI (Alexa 488-EgB4-NB, blue) or DIII (Alexa 488-Afﬁbody, red). The
bar chart was derived from the measurements in Supplementary Fig. 10. (As predicted by the model, EGFR also forms oligomers on cells treated with 200
nM 9G8-NB (Supplementary Fig. 11a, b). f Two-colour SPT on live cells at 37 °C showing the fraction of tracks where two particles labelled with Alexa 488-
Afﬁbody and CF640R-Afﬁbody spent ≥5 frames (250ms) together within <1 pixel (pairwise particle colocalisation fraction) for cells expressing ΔC-EGFR,
wtEGFR and I942E-EGFR. Horizontal spreads separate data points (~5000) within each condition. g Distribution of the duration of pairwise interactions
(τON) in f. Horizontal lines mark mean and SD. Coincidental colocalisation statistics were accounted for12. p-Values (two-tailed Kolmogorov–Smirnov test)
are in Supplementary Fig. 12. h Front view of a ligand-free oligomer illustrating the separation between non-interacting ICM units predicted by extracellular
head-to-head interactions. All panels: DI, green; DII, red; DIII, blue; DIV, dark grey; plasma membrane, yellow; TM, grey; TKD silver
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consistent with the requirement for DIV–DIV contacts for
stabilisation of a functional aTKD dimer (Fig. 5c).
We next used FRET to measure the separations from DI and
DIII to the membrane in erlotinib-bound wtEGFR. Assuming an
upright orientation, the similar DI- and DIII-membrane separa-
tions found are consistent with a non-extended conformation, as
that predicted by the stalk-to-stalk dimer (Fig. 5j). In turn, error
analysis of the FRET data conﬁrms a conformation different from
that of naked wtEGFR (Supplementary Fig. 10a, c, Supplementary
Table 4). To investigate conformational ﬂexibility, we compared
the binding of 9G8-NB to erlotinib-bound wtEGFR and naked
wtEGFR. We found that 9G8-NB, which stabilises the tether42,
displays greater binding to erlotinib-bound wtEGFR (Fig. 5k),
consistent with a greater ability to adopt a tethered conformation.
This would be afforded by the increased ﬂexibility of the stalk-to-
stalk dimer.
wtEGFR + erlotinib + affibody
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We next reasoned that, if the stalk-to-stalk and aTKD dimers
are not just linked across the membrane, but conformationally
coupled, the stabilisation of the sTKD dimer6,10,22 might promote
an ECM dimer different to the stalk-to-stalk dimer, and possibly
similar to the ligand-free back-to-back architecture proposed by
MD simulations23 (Fig. 1d). To test this possibility, we examined
L680N-EGFR, in which a mutation in the N-lobe of the kinase
domain hinders the aTKD dimer interface10. L680N is analogous
to I682Q, which gave rise to the 5CNN6 crystallographic sTKD
structure. As shown in Fig. 5l, the dominance of a different
DIII–DIII separation in L680N-EGFR (in this case 13 nm)
suggests that the L680N mutation promotes inside-out an
extracellular dimer different to the stalk-to-stalk dimer. Further
evidence for L680N-induced dimerisation is provided by the
increased number and duration of the interactions holding
L680N-EGFR dimers together (p < 0.01, Kolmogorov–Smirnov
test, two-tailed) (Fig. 5e, f). The distribution of DIII–DIII
separations also displays fewer separations (>20 nm) than in
wtEGFR (Fig. 5b), suggesting that formation of the sTKD dimer is
incompatible with the head-to-head interface.
FRET results from L680N-EGFR showed a greater separation
from DI to the membrane than from DIII (Fig. 5j). These results
argue that the dimers formed by L680N-EGFR are upright and
adopt an extended conformation49. Given that the dimension of
the Afﬁbody is 3.7 nm37, the 13 nm DIII–DIII separation is
within range of the predictions of the ligand-free back-to-back
dimer, in which the distance between binding sites is ~7 nm. In
turn, the lower binding of 9G8-NB to L680N-EGFR than to
wtEGFR bound to erlotinib (Fig. 5k) is consistent with the smaller
conformational ﬂexibility expected in the back-to-back dimer.
The data therefore argue that the aTKD (sTKD) dimer is
structurally coupled across the plasma with the previously
proposed stalk-to-stalk (back-to-back) dimers.
Inside-out signals regulate cancer mutant dimer geometry. To
investigate changes in ligand-free EGFR structure accompanying
dysregulated signalling, we examined L834R-EGFR and T766M-
EGFR (or L858R and T790M in numbering that include the 24
amino acids signal peptide). These two mutations are prevalent in
non-small cell lung cancer (NSCLC) and located within exons
18–21 in the vicinity of the ATP-binding site (Fig. 6a). L834R-
mutated NSCLC tumours respond to ﬁrst-generation TKIs (like
erlotinib)50. T766M increases the afﬁnity for ATP and confers
resistance to ﬁrst- and second-generation TKIs51. Western blots
conﬁrmed the constitutively phosphorylated status of these
mutants (Supplementary Fig. 17). We collected FLImP data and
compared the results with wtEGFR, ΔC-EGFR, wtEGFR+
erlotinib and wtEGFR+MβCD, and L680N-EGFR (Fig. 6b–e).
As positive control for kinase-mediated dimerisation we used
Δ973-EGFR, in which truncation of the C-terminus abolishes the
autoinhibitory interaction with its own kinase6. As negative
control we used Δ698-EGFR, which lacks the kinase domain.
From the FLImP distributions we quantiﬁed the DIII–DIII
separations consistent with 5 nm (green), 13 nm (yellow), <15 nm
(pink) and >20 nm (blue) (Figs. 6b–e). Consistent with results
above (Fig. 5), we found that oligomers (>20 nm) are reliably
more abundant when one would not expect kinase-mediated
dimerisation (Fig. 6b). Indeed, Fig. 6c shows the FLImP
distributions of the three conditions displaying more oligomers.
Unsurprisingly, with wtEGFR (low phosphorylation) and ΔC-
EGFR (no ICM), we found Δ698-EGFR (no TKD). In contrast,
oligomers were consistently depleted in conditions where one
would expect kinase-mediated dimerisation. Among these con-
ditions, Fig. 6d shows the distributions for wtEGFR upon
erlotinib or MβCD treatments, in which the formation of the
aTKD dimer promotes a dominant ~5 nm component that
reports the formation of stalk-to-stalk ECM dimer at the expense
of head-to-head interfaces, as shown in Fig. 5. In this group, we
also found L834R-EGFR, in which the L834R mutation stabilises
the aTKD dimer interface by suppressing the intrinsic disorder in
the N-lobe kinase dimerisation interface52. According to
conformational coupling, the dominant 5 nm FLImP peak and
fewer oligomers found in L834R-EGFR would suggest that the
stabilisation of the aTKD dimer also promotes the stalk-to-stalk
dimer in this cancer mutant. We used FRET to validate this
notion (Supplementary Fig. 10e). (Later we also discuss the
similarity of the results for L834R-EGFR and wtEGFR under
erlotinib and MβCD treatments with additional data (Fig. 7).)
Lastly, Fig. 6e shows distributions with a sizeable 13 nm
component and a depleted oligomer population. Consistent with
conformational coupling, inhibition of the aTKD dimer in
L680N-EGFR is reﬂected by the relatively lower 5 nm component
in this group. In contrast, the sizes of the 5 and 13 nm peaks,
resolved by BIC analysis (Supplementary Fig. 11c, d), are
comparable in T766M-EGFR and Δ973-EGFR, whose trans
activation depends on the formation of the aTKD dimer51. We
were reassured to ﬁnd that deletion of the C-terminus (Δ973-
EGFR) resulted in oligomer loss and the promotion of dimers
(Fig. 6b–e). This is consistent with the role of the C-terminus in
preventing kinase-mediated dimerisation53.
T766M-EGFR can form symmetric tyrosine kinase dimers. We
were surprised to ﬁnd signiﬁcant numbers of 13 nm separations
in the constitutively phosphorylated T766M-EGFR (Fig. 6e). If, as
Fig. 5 Kinase-mediated ligand-free dimers adopt two ECM dimer architectures. a FLImP distribution (grey) of DIII–DIII separations between CF640R-
Afﬁbody molecules bound to wtEGFR on CHO cells treated with 1 μM erlotinib, compiled from 29 FLImP measurements (CI≤ 6 nm), decomposed into a
sum of four components. The concentration of CF640R-Afﬁbody was 4 nM. b Number of measurements consistent with the mean distances resolved in
the FLImP distribution of wtEGFR (Fig. 2b) (associated FLImP distributions in Supplementary Fig. 13). Errors were assesed with bootstrap-resampling12. c
wtEGFR and IIIV/KKRE-EGFR phosphorylation in Y1173 on CHO cells treated or untreated with 10 mM MβCD. Box plots show inclusive median as a line,
25th and 75th quartile as edges, calculated on n= 3 repeats (representative western blots in Supplementary Fig. 14). d As a treated with 10 mMMβCD,
from 20 FLImP measurements (CI≤ 7 nm). e Pairwise particle colocalisation fraction from two-colour SPT on live cells at 37 °C. f Duration of pairwise
interactions (τON) in e. Horizontal spreads separate data points (~5000) within each condition. g Crystal structure of tethered wtEGFR (PDB ID 1NQL5)
highlighting the location of I545K, I556K, I562R, and V592E (yellow). Colours: DI (green), DII (red), DIII (blue), DIV (grey), EGF (orange). h Head-to-head
dimer highlighting the residues mutated in the IIIV/KKRE mutant (yellow). i As a but for the IIIV/KKRE-EGFR mutant from 22 FLImP measurements with
CI≤ 7.5 nm. j FRET-DOCA from DI (blue) and DIII (red) to the membrane for wtEGFR+ erlotinib, and L680N-EGFR, derived from measurements in
Supplementary Fig. 10. FRET probes as in Fig. 4e. k Ratio between CF640R-9G8-NB and Alexa 488-EgB4-NB binding after chemical ﬁxation. wtEGFR, blue;
wtEGFR+ erlotinib, green; L680N-EGFR, red. Line, median; box edges, 25th and 75th quartile, crosses 5th and 95th quartile, calculated over 30 repeats.
Example images and analysis are in Supplementary Fig. 15. l As a but for L680N-EGFR-expressing cells, from 20 FLImP measurements (CI≤ 6 nm). Lower
resolution (8 nm) versions of a, d, and l with ~2-fold more FLImP measurements show the proﬁle of the distributions is conserved (Supplementary Fig. 16)
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shown by FLImP and FRET results for L680N-EGFR, this peak
reports extended back-to-back dimers, and, as proposed by MD
simulations23, this dimer is structurally coupled to the sTKD
dimer, then, counterintuitively, our results predict that T766M-
EGFR forms signiﬁcant numbers of sTKD dimers. To investigate
this unexpected prediction, we carried out MD simulations of the
sTKD dimer and reanalysed fully converged free-energy land-
scapes from parallel tempering metadynamics (PTmetaD) simu-
lations, in the well-tempered ensemble for wtEGFR and T766M-
EGFR, as in Sutto et al.34.
We reweighted the MD trajectories and projected the free-
energy surface (FES) onto the helical content of the αC helix and
the contact map corresponding to the active (open) state. As
expected, the FES for wtEGFR shows a single global minimum
that corresponds to the intact αC helix with the A-loop in the Src-
like inactive conformation (Fig. 6f, left). There is also a higher-
energy minimum populated with structures with a disordered αC
helix. In the case of T766M mutant, this minimum is broader and
shifted towards lower values that correspond to higher disorder of
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Fig. 6 Kinase-mediated regulation of ECM dimer geometry in cancer-associated intracellular mutants. a Kinase domain structure showing the positions of
relevant amino acids. b Fractions of FLImP measurements whose ranges of 69% conﬁdence overlap with the ranges of DIII–DIII separations expected for
dimers (0–15 nm) (pink) or oligomers (20–60 nm) (blue) collected from cells expressing the receptor mutants and/or under the conditions noted in the X-
axis. The associated FLImP distributions are in Supplementary Fig. 18. c–e The FLImP distributions (grey) and the distributions compiled from the FLImP
measurements whose 69% CIs overlap with DIII–DIII separations= 5 nm (green), 13 nm (yellow), or >20 nm (blue) collected from cells expressing
wtEGFR, ΔC-EGFR, Δ698-EGFR, wtEGFR on cells treated with 1 μM erlotinib, wtEGFR on cells treated with 10mMMβCD, L834R-EGFR, L680N-EGFR,
Δ973-EGFR and T766M-EGFR. The insets show the fraction of separations consistent with each distance. Errors were assesed with bootstrap-
resampling12. f Free-energy surfaces as a function of the helical content of the αC helix and the distance from the reference active conformation (a contact
map corresponding to the active extended A-loop conformation) as obtained from PTmetaD simulations of the wtEGFR and T766M-EGFR mutant. The
central structures of the most populated clusters are shown (left and middle). The A-loop is coloured green, while the αC helix is shown in purple if it forms
an α-helix and in pink if it forms a 310 helix. Salt-bridge interactions formed at the dimer interface in the last µs of the unbiased MD simulations of the
symmetric dimers (right panel). The mean values and the standard deviations are calculated across monomers. The salt bridge was considered to be
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Fig. 7 Equilibrium between the aTKD and sTKD dimers. a Cartoon of the two dimer conﬁgurations of the kinase domain. Starting from the aTKD dimer, a
counter clockwise rotation of the activator (blue) along its vertical axis followed by a clockwise rotation along an axis perpendicular to the plane will allow
the sTKD to form. b The FLImP distribution (grey) and the distributions compiled from the FLImP measurements whose 69% CIs overlap with DIII–DIII
separations= 5 nm (green), 13 nm (yellow), or >20 nm (blue) collected from cells expressing K721A-EGFR compiled from 29 FLImP measurements with
CI≤ 7 nm. The inset shows the fraction of separations consistent with each distance. Errors were assesed with bootstrap-resampling12. c Fraction of tracks
where two different-colour particles labelled with Alexa 488-Afﬁbody and CF640-Afﬁbody spent ≥5 frames (250ms) together within <1 pixel (denoted
fraction of pairwise particle colocalisation fraction) and d distribution of the duration of these pairwise interactions (τON). Horizontal spreads separate data
points (~5000) within each condition. Horizontal white lines mark the mean and SD. Coincidental colocalisation statistics were accounted for. e, f As
c, d but in the presence of 10 mMMβCD. p-Values of the signiﬁcance of differences between conditions are in Supplementary Fig. 20
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αC helix is also present and both minima are populated with
structures with an active A-loop conformation.
These results indicate that the T766M mutation has two effects.
On the one hand, it is clear from the converged FES of the
monomer that it destabilises the aTKD dimer interface by
affecting the stability of the αC helix. On the other, the long MD
simulations of the sTKD dimer in wtEGFR and T766M-EGFR
show more stability for the single mutant (as indicated by root-
mean-square ﬂuctuations, Supplementary Fig. 19a) and suggest
that T766M stabilises the sTKD dimer through a network of
interactions (Fig. 6f (right), Supplementary Fig. 19b). In
particular, as shown in Supplementary Fig. 19c, we see that
Q767 engages in interactions with the interface residues (such as
E981) located below the AP-2 helix that refolds in this dimer (it is
disordered in the monomer). Further evidence to this observation
comes from Jura et al.22 where it is shown the E981R mutation
facilitates EGFR phosphorylation. This implies that the inactive
sTKD cannot form.
The aTKD/sTKD dimer equilibrium depends on the C-
terminus. The ﬁnding of signiﬁcant numbers of sTKD dimers
in the constitutively active T766M-EGFR, but not in wtEGFR
(Fig. 6f), argues against a main autoinhibitory role for the sTKD
dimer25. Alternatively, in the absence of structural impediments,
kinase-mediated dimerisation might inherently give rise to both
active aTKD and inactive sTKD dimer conﬁgurations (Fig. 7a).
Recently, solid state NMR showed that EGFR structure is
dynamic54, suggesting that different conformations may exchange
in time. This is supported here by three observations: ﬁrstly, in
L834R-EGFR, where the aTKD dimer interface is super-stable52,
there are few sTKD dimers (Fig. 6d); secondly, in L680N-EGFR,
in which the aTKD dimer is inhibited, the sTKD dimer popula-
tion is boosted (Fig. 6e); and thirdly, in the absence of constraints,
comparable numbers of aTKD and sTKD dimers form (like in
T766M-EGFR) (Fig. 6e). Indeed, K721A-EGFR, in which the
lysine 721 to alanine mutation in the ATP-binding pocket renders
the kinase dead55, is another example in which both aTKD and
sTKD dimers form at the expense of oligomers (Fig. 7b). This
result highlights the critical role played by the kinase core in
regulating distal dimerisation interfaces56 and the challenges
associated to intervening with TKIs.
To test the equilibrium hypothesis we examined the effect of
mutations on the kinetics of particle interactions. Crucially, we
can interpret SPT results knowing the stoichiometry and
architecture of the different conditions (Figs. 2–6). Results reveal
that the kinase-mediated dimers induced by the L834R, L680N,
and T766M mutations are more abundant (Fig. 7c) and longer
lived (Fig. 7d) than the extracellular head-to-head interfaces
formed by wtEGFR (p < 0.01). T766M-EGFR and L680N-EGFR
dimers are similarly stable (Fig. 7c), underscoring the preference
of T766M-EGFR for the sTKD dimer.
Also shown in Fig. 7c, d, the dimers induced by C-terminal
truncation in Δ973-EGFR are fewer than those induced by the
L834R, L680N, and T766M mutations. This is consistent with the
pivotal role played by the C-terminus in the stabilisation of active
and inactive kinase dimers6,22. In turn, the low stability of the
dimers formed by K721A-EGFR is consistent with the key role
played in stabilising dimer interfaces by the opening and closing
of the ATP-binding site during ATP hydrolysis56.
Using coarse-grained metaDynamics free-energy calculations,
Lelimousin et al.57 proposed that a change in bilayer thickness,
such as that induced by cholesterol depletion58, promotes a
transition from less stable TM domain dimers, including the C-
crossing conﬁguration associated to the sTKD23, to the most
stable N-crossing TM dimer. Given this, we speculated that if
receptor populations bearing sTKD and aTKD dimers are in
equilibrium, we could alter the kinetics by depleting plasma
membrane cholesterol. Indeed, MβCD promotes in T766M-
EGFR an increase in the number of dimers48 (Fig. 7c, e) in which
the duration of the interactions is consistent with the formation
of active aTKD dimers. The latter is borne by the striking
similarity between T766M-EGFR+MβCD with wtEGFR+
MβCD and L834R-EGFR (Fig. 7f). Note these dimers are
phosphorylated, and hence longer lived than erlotinib-bound
wtEGFR dimers (Fig. 5f). As the predicted equilibrium would
dictate, cholesterol depletion does not increase the number of
dimers formed by L834R-EGFR, which is depleted of sTKD
dimers (Fig. 6d), or L680N-EGFR, where the N-lobe mutation
inhibits the aTKD dimer (Fig. 7d, f). These results are therefore
not only consistent with a shift in the equilibrium from sTKD to
aTKD dimer conﬁguration, but also with the key role predicted
for motion correlations between the TM, JM and kinase domains
in the stabilisation of the aTKD dimer56. Interestingly, the shift in
equilibrium from sTKD to aTKD dimer does not take place in
Δ973-EGFR, but it is strongly present in K721A-EGFR, showing
that the equilibrium between kinase dimer conﬁgurations
depends on the C-terminus and not just on phosphorylation.
Discussion
In summary, the body of data reported here describes the
architectures of three EGFR non-monomer ligand-free species
populating the cellular basal state (Fig. 8). We propose a
structural model of a polymer chain assembled through a pre-
viously undiscussed extracellular head-to-head interaction.
Investigations on intracellular mutants and treatments found no
evidence of intracellular interactions in the head-to-head poly-
mers. The proposed role of the head-to-head interaction is
therefore two-fold. On the one hand, it drives oligomer assembly,
thereby bringing receptors together and priming them for a
quick response to growth factor. On the other, it maintains TM
helices sufﬁciently apart to oppose the formation of kinase-
mediated dimers. Indeed, kinase-mediated dimerisation breaks
the head-to-head interaction, suggesting the latter is important
for autoinhibition.
The curved architecture of head-to-head polymers provides an
elegant solution to the autoinhibition conundrum. Achieved via
homo-extracellular interactions, such curved architecture delivers
the largest possible consistent separation between TM helices in
multimers, while assembling polymers commensurate with the
diameter around relevant plasma membrane vesicles45. The head-
to-head interaction averts the two-fold symmetry advantageous to
kinase-mediated interactions, and, by holding receptors via DI,
also averts highly dynamic monomer ﬂuctuations that could lead
to fortuitous dimerisation54. The bulk of the amino acids involved
in the head-to-head interaction are deleted in EGFRvIII44, pro-
viding a rationale for the transformation potential of this
mutant59.
Conformational coupling was demonstrated in the ligand-
bound state40. Here, in the ligand-free state, it is supported by the
ﬁnding that kinase-mediated dimerisation and its requirement to
form TM helix dimers, breaks head-to-head dimers and polymers
inducing across the plasma membrane the formation of two
dimer species, both distinct from the head-to-head dimer, the
architectures of which were previously reported by long-timescale
MD simulations23 and EM experiments26. One kinase-mediated
extracellular dimer is upright and extended, and consistent with a
back-to-back conformation23. Results for L680N-EGFR together
with MD simulations for the T766M mutant exploiting fully
converged free-energy landscapes validate the prediction that the
extended dimer is structurally coupled to the sTKD dimer23. The
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second is a stalk-to-stalk dimer formed by DIV–DIV contacts and
structurally coupled to the aTKD dimer26. Our results suggest
that kinase-mediated dimer conformations coexist in equilibrium
in constitutively active and in inactive receptor dimers, regulated
by C-terminal interactions54,56.
One key question remains. If the inactive sTKD dimer readily
forms in constitutively active receptors, but not signiﬁcantly in
wtEGFR, what is its role if not autoinhibitory? It is tempting to
speculate that the ligand-free EGFR structures we propose may be
applicable to other HER family members. Indeed, recent results60
show that, by stabilising a particular HER2 conformer, the TKI
lapatinib drives the formation of a HER2–HER3 kinase domain
heterodimer via a symmetric interface. The lapatinib-induced
HER2–HER3 heterodimer is primed to respond to neuregulin,
leading to signal ampliﬁcation. It will be interesting to ascertain
the possibility of an analogous role for the sTKD dimer.
Methods
Cell culture. All reagents unless otherwise stated were from Invitrogen, UK. CHO
cells expressing wtEGFR or the ΔC-EGFR, Δ973-EGFR, K721A-EGFR, Δ698-
EGFR, L680N-EGFR mutants under an inducible Tet-ON promoter35,61 were a gift
from Prof. Linda Pike (Washington University, St. Louis). They were grown in 5%
CO2 in air at 37 °C in phenol-red free Dulbecco’s modiﬁed Eagle's medium
(DMEM) supplemented with 10% (v/v) foetal bovine serum, 2 mM glutamine, 100
μg/ml hygromycin B, and 100 μg/ml geneticin. Cells transiently transfected with
I942E-EGFR, L834R-EGFR, IIIV/KKRE-EGFR, control wtEGFR or T766M-EGFR
were allowed to grow for 48 h after transfection. All cells used were regularly tested
for mycoplasma contamination.
Drug treatments. For all relevant experiments cells were treated with 1 μM
erlotinib (Tocris Bioscience) in medium containing 0.1% serum during starvation
and labelling, and imaging (for live cells). Cholesterol depletion was performed by
incubating cells with 10 mM methyl beta-cyclodextrin (MβCD) (Sigma) in Opti-
MEM (Invitrogen) for 30 min at 37 °C after the starvation step. Cells were rinsed
twice with medium with 0.1% serum prior to labelling.
Fluorophore localisation imaging with photobleaching. The method was ﬁrst
described in ref. 28. Brieﬂy 1 × 105 CHO cells were seeded on 1% BSA-coated 35
mm no. 1.5 (high tolerance) glass-bottomed dishes (MatTek Corporation, USA) in
2 ml of media plus 50 ng/ml of doxycycline hyclate (Sigma), resulting in expression
of ~105 receptors/cell35. After 48 h the medium was changed to 0.1% serum plus
50 ng/ml doxycycline for 2 h. Cells were rinsed and cooled to 4 °C for 10 min and
then labelled with 4 nM CF640R-EGF or CF640R-Afﬁbody, or with 8 nM EgB4-NB
for 1 h on ice. The N-terminus of EGF was labelled at a 1:1 ratio by Cambridge
Research Biochemicals (Cleveland, UK). The EGFR Afﬁbody was labelled at a 1:1
ratio at its single cysteine residue. EgB4-NB was conjugated to CF640R-NHS ester
(Biotium) according to the manufacturer’s instructions. Cells were rinsed and ﬁxed
with 3% paraformaldehyde (Electron Microscopy Sciences, USA) plus 0.5% glu-
taraldehyde (Sigma) for 15 min at 4 °C, then 15 min at room temperature. If
required, cells were pre-treated for 1 h on ice at 4 °C with 200 nM 9G8-NB dis-
solved in PBS, or with erlotinib or MβCD as described above. We used an Axiovert
200M microscope with TIRF illuminator (Zeiss, UK), with a ×100 oil-immersion
objective (α-Plan-Fluar, NA= 1.45; Zeiss, UK) and an EMCCD (iXon X3; Andor,
UK). The microscope is also equipped with a wrap-around incubator (Pecon XL
S1). Samples were illuminated with a ﬁbre-coupled laser combiner (Andor) with a
100 mW 640 nm diode laser (Cube, Coherent). Images were collected every 0.28 s.
Typically, for each experiment, approximately 120,000 single particle image spots
were obtained from at least 750 cells and at least three biological repeats. Empirical
posterior FLImP distributions were then obtained based on Afﬁbody, EGF, or
EgB4-NB separation measurements.
FLImP decomposition and post-analysis. The method has been described in
detail in ref. 12. Brieﬂy, a FLImP histogram is a sum of multiple FLImP mea-
surement empirical posterior distributions, and can be modelled as sum of Rician-
distributions, one for each discrete underlying separation. We use a Bayesian
parameter estimation to ﬁt a given number of Rician components to the FLImP
distribution, thus inferring the underlying distances, their uncertainties, and the
number of measurements for each component. We use a BIC to choose objectively
the number of components justiﬁed by the data. We incorporate bootstrap-
resampling of the measurements to account for the effect of the ﬁnite number of
measurements on the error bars and BIC test.
Photo-bleaching imaging correlation spectroscopy. Fluorescent images of the
labelled receptor at the basolateral membrane were repetitively scanned with an
Olympus FV1000 laser scanning confocal microscope to induce partial photo-
bleaching. The resulting images were subjected to pbICS as described in ref. 38.
Brieﬂy, for the “model-free” analysis, an aggregation model with monomer, dimer,
trimer, tetramer, pentamer, hexamer, septamer, and octamer was assumed, where
the fraction of each oligomeric species was variable and allowed to ﬂoat in the
ﬁtting of the pbICS curves. The reported histogram is the cumulative average of
seven pbICS curves per treatment condition, acquired over three independent
biological replicates.
The derived cluster density (CD) as a function of fractional intensity remaining
after each round of photobleaching (p) is given by Eq. (1).






j jcj þ j j 1ð Þcjp
h i ; ð1Þ
Where j is the oligomer size (j= 1 for monomer, j= 2 for dimer, etc.) and cj is the

























Fig. 8 Cartoon models of ligand-free EGFR species on the cell surface. a, b Autoinhibited ligand-free receptors form a dimers and b larger oligomers via
extracellular head-to-head interactions. Within head-to-head dimers and oligomers the ICMs remain as non-interacting units. c, d Kinase-mediated
receptor dimerisation outcompetes head-to-head interactions to form two types of receptor dimers that typically coexist in equilibrium (bearing aTKD and
sTKD dimer conﬁgurations). Head-to-head dimers and oligomers are disrupted by kinase-mediated dimerisation independently of whether the driver
mutation and/or treatment is activating or not. The ECM architecture of one dimer type is consistent with a back-to-back dimer and structurally coupled to
an sTKD dimer6,22 (c). The ECM architecture of the other is consistent with a stalk-to-stalk dimer and structurally coupled via an N-terminal TM crossing
to the aTKD dimer40 (d). The L680N kinase domain mutation shifts the equilibrium toward the dimer population bearing sTKD dimers while L834R shifts
the equilibrium towards the dimer population bearing the aTKD dimer. For all panels, DI is in green, DII in red, DIII in blue, DIV, TMD and JMD in grey, TKD
in silver
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3, 4, 5, 6, 7, 8 and allowed the concentrations C1…C8 to vary62. A typical raw
dataset (CD versus p) together with ﬁt is shown in Supplementary Fig. 3.
FRET distance of closest approach. Uncoated 35 mm no. 1.5 glass-bottomed
dishes were seeded with 1 × 105 CHO cells expressing wtEGFR in 2 ml of media
with 250 ng/ml of doxycycline (~4 × 105 receptors/cell). After 48 h, the medium
was changed to 0.1% serum with the same concentration of doxycycline for 2 h.
Samples were labelled with 5 µM C18 DiI (Thermo Fisher Scientiﬁc) for 10 min at
37 °C, then with either 100 nM EGFR Afﬁbody or 200 nM EgB4-NB both labelled
with Alexa Fluor 488 (custom conjugation) at 4 °C on ice for 1 h. Samples were
ﬁxed with 3% paraformaldehyde plus 0.5% glutaraldehyde as described above. The
ensemble averaged DOCA of EGFR-bound Alexa 488 probes to cell membranes
loaded with the ﬂuorescent lipid analogue C18DiI was estimated from the measured
FRET efﬁciencies for increasing acceptor density within the membrane using the
procedure described previously32. Brieﬂy, bootstrap regression analysis was per-
formed by randomly resampling datasets with replacement 3000 times and ﬁtting
each resampled dataset to the FRET response generated by Monte-Carlo simulation
of a donor placed at increasing distances above a plane of acceptors. For each
dataset a distribution of possible DOCAs is generated and the mean and standard
deviation of these distributions are reported. Bootstrap hypothesis testing was used
to compare differences between mean DOCAs. For each pair of datasets compared,
bootstrap regression analysis was performed by resampling with replacement from
the pool of the combined data points, two new datasets of equal size to the ori-
ginals. The test statistic was calculated for each of 10,000 bootstrap replicates to
generate a test distribution corresponding to the null hypothesis that the difference
between the mean DOCA values is zero. The p-value reported is the proportion of
the test distribution larger than the observed test statistic. The number of data
points (each point from an individual cell) for wtEGFR+Afﬁbody, wtEGFR+
EgB4-NB, wtEGFR+ 9G8-NB+Afﬁbody, wtEGFR+ 9G8-NB+ EgB4-NB,
wtEGFR+ erlotinib+Afﬁbody, wtEGFR+ erlotinib+ EgB4-NB, L680N-EGFR+
Afﬁbody, L680N-EGFR+ EgB4-NB, L834R-EGFR+Afﬁbody, and L834R-EGFR
+ EgB4-NB are 54, 63, 97, 30, 119, 170, 40, 47, 30, and 11, respectively. Data were
taken from at least two independent biological replicates.
Western blots. CHO cells were seeded in six-well plates at a density of 1 × 105
cells/dish. 48 h later, cells were washed twice with ice-cold PBS chilled for 10 min
then incubated on ice with ice-cold EGF for 1 h at 4 °C. Cells were washed twice
with ice-cold PBS and scraped into PBS plus inhibitors (phosphatases and pro-
teases) and spun down. Cells were lysed in 10× volume of M-PER lysis buffer
(Pierce)+ 100 mM NaF+ 1 mM Na3VO4+ 1% protease inhibitors (Cell Signalling
Technologies)+ 150 mM NaCl+ 1 mM EDTA at pH 8 and incubated for 10 min
at room temperature. Cells were cleared by centrifugation and total protein mea-
sured. Sample buffer was added to 1× ﬁnal concentration. Samples were run in
parallel on 1.5 mm thick, 3–8% Tris-Acetate NuPAGE gels (Invitrogen) with
HiMark Prestained HMW and Novex Sharp Prestained protein standards (Invi-
trogen) using an XCell apparatus (Invitrogen). Proteins were blotted using an iBlot
system (Invitrogen) on PVDF membranes, blocked for 1 h at 4oC with 5% BSA in
TBS+ 0.1% Tween and probed overnight with mouse anti-EGFR pY1173 (Upstate
(Millipore)—cat. no. 05–483) antibody diluted 1/1000. Gels were probed with
secondary anti-mouse-HRP antibody (Jackson ImmunoResearch—cat. no. 715-
035-150) diluted 1/1000 and incubated with Supersignal West Pico Chemilumi-
nescent Substrate solution (Pierce) for 5 min, then imaged with a BioRad Che-
miDoc MP system imager. Each blot was stripped with 25 ml stripping buffer (2%
SDS, 0.75% β-mercaptoethanol, 62.5 mM Tris HCl pH 6.7) for 50 min at 60 °C, and
re-probed with an anti-EGFR cocktail composed of anti-EGFR D38B1 (Cell Sig-
nalling Technologies—cat. no #4267), anti-EGFR N-Terminal polyclonal ab137660
(abcam), and anti-EGFR polyclonal 10005: sc-03 (Santa Cruz Biotechnology), each
diluted 1/2000, all derived from rabbit. Anti-rabbit HRP (Jackson ImmunoR-
esearch—cat. No 711-035-152) diluted 1/1000 was used for all blots and images
were acquired as above. Densitometry was performed using Fiji63 to extract the
intensity of the bands and then calculating the ratio between the intensity of the
pY1173 EGFR band and the corresponding total EGFR band for each condition.
Experiments were performed in triplicate and data were presented in a box and
whisker plot, showing the inclusive median, with the 25th and 75th quartile as box
limits and the ﬁrst and last quartile as whiskers.
Tracking of EGFR complexes on CHO cells. Cells were seeded at a density of 1 ×
105 cells/dish on 1% BSA-coated 35 mm no. 1.5 (high tolerance) glass-bottomed
dishes (MatTek Corporation, USA) in 2 ml of media. Receptor expression in CHO
cells was induced with 50 ng/ml doxycycline. Prior to imaging, cells were starved
for 2 h at 37 °C in 0.1% serum supplemented with 50 ng/ml doxycycline if required.
Treatments with erlotinib and MβCD were performed as described above. Cells
were then rinsed twice with 0.1% serum without doxycycline pre-heated at 37 °C
and were labelled with a 1:1 mixture of 8 nM Alexa 488-Afﬁbody/CF640R-Afﬁbody
for 10 min at 37 °C. Cells were rinsed twice with low serum medium without
doxycycline pre-heated at 37 °C and promptly imaged. Single-molecule images
were acquired using an Axiovert 200M microscope with a TIRF illuminator (Zeiss,
UK), with a ×100 oil-immersion objective (α-Plan-Fluar, NA= 1.45; Zeiss, UK)
and an EMCCD (iXon X3; Andor, UK). The microscope is also equipped with a
wrap-around incubator (Pecon XL S1). The 488 and 642 nm lines of a LightHub
laser combiner (Omicron Laserage GmbH) were used to illuminate the sample and
an Optosplit Image Splitter (Cairn Research) was used to separate the image into its
spectral components as described previously64. The ﬁeld of view of each channel
for single-molecule imaging was 80 × 30 µm. Typically, for each condition, at least
30 ﬁeld of views comprising one or more cells were acquired from a total of at least
3 independent biological replicates. All single-molecule time series data were
analysed using the multidimensional analysis software described previously31.
Brieﬂy, this software performs frame-by-frame Bayesian segmentation to detect
and measure features to sub-pixel precision, then links these features through time
to create tracks using a simple proximity-based algorithm. The software determines
cubic polynomial registration transformations from images of ﬂuorescent beads.
Feature detection and tracking was performed independently in each channel.
Calculation of colocalisation and τON. Two-colour TIRF images of the basolateral
surfaces of cells were chromatically separated by a beam splitter and registered
using custom made software to map the relative positions of the probes over the
time course of data acquisition31. Single particle tracks were extracted as above31.
The fraction of co-localised tracks was reported by tracks in which a receptor
particle in one channel colocalises with another particle in the other channel,
spending at least ﬁve 50 ms frames in total moving together within a pixel of each
other. Coincidental colocalisation statistics were calculated for a dataset as follows.
In each channel, a randomised set of tracks of the same size as the measured set
was produced, where each track in the random sample was chosen (with repla-
cement) from the measured tracks for that channel, recentred at random with
uniform probability density across the ﬁeld of view, rotated through a random
angle with uniform probability density between 0 and 360°, and randomly ﬂipped
in x with probability 0.5. The random tracks therefore have key properties such as
durations and path structures representative of the true tracks, but now rando-
mised in distribution and orientation. The colocalisation statistics were then cal-
culated for the randomised tracks. This was performed a total of 50 times for each
dataset, and the colocalisation statistics pooled to give a ﬁnal estimate coincidental
colocalisation fraction for that dataset. The reported colocalisation fraction is then
the fraction for the real data minus the estimated coincident colocalisation fraction.
The duration (τON) of individual events in which a track in one channel moves
within a pixel of a track in the other channel and then they move apart again was
also calculated. To reduce the impact of localisation error on these results a tem-
poral Gaussian smoothing ﬁlter of FWHM 4 frames (200 ms) was applied to the
position traces before the colocalisation analyses.
9G8 nanobody binding afﬁnity for different receptor conformations. Ectodo-
main conformation was investigated by measuring the binding of 9G8-NB, which
stabilises the tethered conformation, using the ratio between the binding of
CF640R-9G8-NB, a probe which is selective for the tethered state of the receptor,
and Alexa 488-EgB4-NB, a probe which is not, as determined by quantitative
confocal microscopy. Brieﬂy, uncoated 35 mm no. 1.5 glass-bottomed dishes were
seeded with 1 × 105 CHO cells expressing wtEGFR in 2 ml of media with 250 ng/ml
of doxycycline (~4 × 105 receptors/cell). After 48 h, the medium was changed to
0.1% serum with the same concentration of doxycycline for 2 h and cells were
treated with 1 μM erlotinib as described in the drug treatments section above, if
required. Cells were then treated with 50 nM Alexa 488-EgB4-NB for 1 h at 4 °C
and then ﬁxed with 3% PFA for 15 min at 4 °C, followed by 15 min ﬁxation at room
temperature. This was done to prevent 9G8-NB from inducing conformational
changes. After ﬁxation, cells were washed three times with PBS and then treated for
1 h at 4 °C with 200 nM of CF640R-9G8-NB. Twenty confocal images of equatorial
regions of the cells were collected from three replicates, using a Leica TCS SP8
microscope with a (NA= 1.4; Leica) and a Leica HyD hybrid detector. Fluores-
cence was excited with 488 or 640 nm light produced by an NKT Extreme
supercontinuum light source. Using FIJI, regions of interest corresponding to the
plasma membrane of individual cells were drawn manually. The mean Alexa 488
and CF640R ﬂuorescence were measured and the ratio of CF640R:Alexa 488
ﬂuorescence intensity calculated for each cell.
MD simulations of the head-to-head EGFR dimer on membrane. Simulations
were run for two set-ups: with and without VHH nanobody. Each EGFR monomer
in the simulations contained residues 3–650; the VHH nanobody in the model
contained residues 1–124. The ECM of EGFR monomer was obtained from PDB
entry 1NQL5, and loops were built manually to connect the extracellular domains
and transmembrane helix. The EGFR monomers were assembled into a dimer
based on crystal packing contact observed in PDB entry 4KRP42. A VHH nano-
body was added to each EGFR monomer based on the EGFR–VHH complex in
PDB entry 4KRP in the simulation of VHH-bound EGFR dimer. The protein
complexes were placed in/on a membrane consisting of only 1-palmitoyl-2-
oleoylphosphatidylcholine lipids. The above systems were solvated in water with
0.15 M NaCl. Additional Cl– ions were included to neutralise the net charges of the
proteins (+2 total). The simulation systems were parameterised using the Amber
ff99SBstar-ILDN force ﬁeld for proteins65, the CHARMM 36 force ﬁeld for lipids
and ions66, and TIP3P for water67. After relaxation, the system was further equi-
librated in the NPT ensemble for 1 ns using GPU Desmond. The simulation system
of EGFR dimer without VHH nanobody was 17.9 × 17.9 × 17.2 nm3 in dimensions
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and contained 550,717 atoms. The simulated system of EGFR dimer with VHH
nanobody was 21.5 × 21.5 × 19.8 nm3 in dimensions and contained 879,010 atoms.
The simulations were then performed on a special-purpose supercomputer, Anton
2 (ref. 68). Simulations of the EGFR dimer without VHH nanobody ran for 20.0
and 13.8 μs in two repeats, and simulations of the EGFR dimer with VHH
nanobody ran for 20.0 μs in two repeats. Production simulations were performed in
the constant number (N), pressure (P, semi-isotropic), and temperature (T) (NPT)
ensemble with T= 310 K and P= 1 bar using a variant of the Nosé–Hoover69 and
the Martyna–Tobias–Klein algorithm70. The RESPA integration method was used
with time step of 2.5 fs. Long-range electrostatics evaluated every three time steps
using the u-series method with a 1.1–1.3 nm cutoff for the electrostatic pairwise
summation: a 0.9 nm cutoff for the van der Waals calculations. Water molecules
and all bond lengths to hydrogen atoms were constrained using M-SHAKE71.
MD simulations and free-energy calculations. The X-ray structures used as
models for the wild type and T766M mutant sTKD dimer are deposited under the
Protein Data Bank (PDB) codes 5CNO (ref. 6) and 4I24 (ref. 72), respectively. The
missing atoms were built with MODELLER73. Both dimers consist of the sequence
N700-D1014 (in the numbering with the 24-aa tag). For unbiased MD simulations,
each simulated system was generated using AMBER14SB force ﬁeld74 at pH 7.4.
The protonation states of the residues were determined by PROPKA3.0 (ref. 75),
which left all the residues in their usual charge states, except for His805 which was
protonated. The systems were solvated with ~36,000 TIP3P water molecules76 in a
dodecahedral box with periodic boundary conditions, while Na+ and Cl− ions were
added to reach neutrality and the ﬁnal concentration of 0.15M (the total number
of atoms was ~120,000). The production simulations were generated using
GROMACS 5.1.4 biomolecular simulation package77 with a 2-fs integration step,
constant temperature of 310 K using velocity rescale thermostat, and constant
pressure of 1 bar. Further simulation details can be found in Supplementary
Methods. For free-energy calculations, fully converged free-energy landscapes of
the wild type and single mutant monomers were obtained by parallel tempering
metadynamics78 simulations in the well-tempered ensemble (with 6 replicas per
system and ~680 and ~610 ns per replica, respectively34). The free energies were
initially projected as a function of three collective variables: the difference between
two salt-bridge distances: d(K721, E738)–d(K721, D834) which were found to
switch during the activation, and two contact maps (one corresponding to the Src-
like inactive state and the other corresponding to the active extended state). FESs as
a function of a variable that captures the α-helical content of the protein
(ALPHARMSD with default settings) and a contact map corresponding to the
active extended A-loop conformation (distance from the reference structure) were
obtained by reweighting the trajectories and the converged FESs34 using the
PLUMED 2.3.2 library79. Further analysis details can be found in Supplementary
Methods.
Plasmids and transfections. The I942E-EGFR pcDNA3 plasmid and IIIV/KKRE-
EGFR plasmid were gifts from Prof. J. Kuriyan (University of California Berkley).
The wtEGFR pCDNA3 plasmid used as a control in the western blot experiments
was a gift from Prof. Y. Yarden (Weizmann Institute of Science). The L834R-EGFR
pCDNA3 and T766M-EGFR pCDNA3 plasmids were produced through site-
directed mutagenesis using the primers described in Supplementary Table 5.
Reactions were performed using a site-directed mutagenesis kit from Stratagene
following the manufacturer’s instructions. EGFR IIIV/KKRE was ampliﬁed by PCR
using primers containing infusion tags (described in Supplementary Table 5) for
the insertion of the PCR product into the pOPINE vector80 cut with NcoI and PmeI
(gift from Prof Ray Owens, University of Oxford). The In-Fusion® HD EcoDry™
Cloning Plus kit (Takara) was used according to the manufacturer’s instructions.
The ﬁnal product was conﬁrmed by complete sequencing. Transfections were
performed in solution at the same time as seeding, using Viafect (Promega) as a
carrier for the I942E-EGFR, L834R-EGFR, T766M-EGFR and wtEGFR plasmids.
GeneJuice (Merck Millipore) was used as a carrier for IIIV/KKRE-EGFR. In all
cases expression was allowed to proceed for 48 h prior to further experimental
manipulations.
Data availability
Data supporting the ﬁndings of this manuscript are available from the corresponding
author on reasonable request.
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